# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

> **NCT03337022** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 34 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CC-90006
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03337022
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337022, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03337022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*